Rumi Scientific
Biotechnology, 320 Park Ave, New York, 10022, United States, 1-10 Employees
Phone Number: +12*********
Who is RUMI SCIENTIFIC
Rumi Scientific is a research-driven company focused on the discovery of drugs and innovative treatments for human genetic diseases affecting the central nervous system. We have created a...
Read More
- Headquarters: 320 Park Ave, New York, New York, 10022, United States
- Date Founded: 2017
- Employees: 1-10
- Revenue: $1 Million to $5 Million
- Active Tech Stack: See technologies
- CEO: Allen Fienberg
Industry: Biotechnology
SIC Code: 6552
Does something look wrong? Fix it. | View contact records from RUMI SCIENTIFIC
Rumi Scientific Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Rumi Scientific
Answer: Rumi Scientific's headquarters are located at 320 Park Ave, New York, 10022, United States
Answer: Rumi Scientific's phone number is +12*********
Answer: Rumi Scientific's official website is https://rumiscientific.com
Answer: Rumi Scientific's revenue is $1 Million to $5 Million
Answer: Rumi Scientific's SIC: 6552
Answer: Rumi Scientific has 1-10 employees
Answer: Rumi Scientific is in Biotechnology
Answer: Rumi Scientific contact info: Phone number: +12********* Website: https://rumiscientific.com
Answer: Rumi Scientific is a research-driven company focused on the discovery of drugs and innovative treatments for human genetic diseases affecting the central nervous system. We have created an exciting human organoid-based platform that can be used for agnostic drug discovery and can be translated at the level of high-throughput screening. We have unlocked the full potential of human organoid technology for the discovery of tomorrows therapeutics. Our platform harnesses the power of embryonic stem cells to model human development in vitro and combines accurate genetic models of human diseases introduced by gene editing together with multi-cellular self-organization to create defined pathological embryonic tissues that serve as a basis for drug screening using artificial intelligence. While we are pursuing an ongoing drug development effort for Huntingtons Disease, we are also expanding the company focus towards neurodevelopment disorders. We believe that focusing on synthetic human embryology in both normal and disease contexts will open new doors towards treatments for many genetic disorders that still have no cures.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month